- Nawal Ouzren Chief Executive Officer to step down for personal reasons
- Amit Munshi, Chairman of Sensorion to assume role of Interim CEO
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Nawal Ouzren, Sensorion’s Chief Executive Officer and a Director on the Company’s Board, is stepping down from both posts due to a personal matter incompatible with serving as Chief Executive Officer. Amit Munshi, who serves as the Chairman of Sensorion will assume the role of Interim Chief Executive Officer and Ms. Ouzren will remain temporarily as a consultant to the Company to ensure an effective transition. This leadership change is effective immediately and the Board has commenced its search for a permanent Chief Executive Officer.
“Since taking on the role of Chief Executive Officer back in 2017, it’s been an absolute pleasure to work with the entire Sensorion team as we embarked on an ambitious journey to provide best-in-class restoration therapeutics and preventive treatments for hearing loss disorders that impact millions of patients across the globe,” commented Nawal Ouzren. “While unexpected, my departure comes at a time when the Company is well positioned to execute on its clinical and corporate development plan having recently completed an important financing milestone anchored by strategic investor Sanofi which enables the advancement of key pipeline assets to significant value inflection points while strengthening the balance sheet. I leave the Company with a strong management team in place and will work with Amit to facilitate a smooth transition. Moving forward, I wish the Sensorion team best wishes as it continues its critical mission to help patients suffering from a variety of hearing loss conditions.”
“On behalf of the Board, I wish to thank Nawal for her exceptional leadership during her tenure as Chief Executive Officer“ commented Amit Munshi, Sensorion’s Chairman of the Board and Interim CEO. “I look forward to working with my fellow Board members and the management team to maintain our clinical development timelines and corporate growth objectives.”
The Company recently announced (January 26th, 2026) a €60 million placement reserved to specific categories of investors and led by Sanofi with participation from top tier healthcare dedicated institutional investors. This transaction is an important milestone for Sensorion’s evolution. Its proceeds will mostly be allocated to advancing the Company’s pipeline of next generation gene therapy candidates while providing sufficient cash runway through the end of H1 2027. The programs that are being prioritized include SENS-601 (GJB2-GT) targeting hearing loss associated with GJB2 mutations which are responsible for the most frequent type of congenital deafness, accounting for approximately 50% of autosomal recessive non-syndromic congenital hearing loss and also implicated in early-onset forms of severe presbycusis in adults. The Company is on track to submit SENS-601’s clinical trial application submission in Q1 2026. Other clinical development milestones in Q1 2026 include cohort two 6 months follow-up data reporting of the Phase 1/2 Audiogene trial for SENS-501 which targets hearing loss related to mutations in the GJB2 gene.
